MED BIOGENE INC.
598 East Kent Avenue South
Vancouver, BC V5X 4V6
Phone: 604-732-7332

NEWS RELEASE

MED BIOGENE INC. - CONSOLIDATION

Vancouver, British Columbia, November 30th 2017 – Med BioGene Inc. ("MBI" or the "Company") (TSXV: MBI) announces that pursuant to a resolution approved by the board of directors, the Company intends to consolidate (the "**Consolidation**") its issued and outstanding common shares (the "**Shares**") on a 10 old shares for 1 new share basis, subject to the approval of the TSX Venture Exchange. The Company currently has 87,578,353 Shares outstanding and following the Consolidation will have 8,757,835 Shares outstanding, assuming no other Shares of the Company are issued. The name of the Company and stock trading symbol will remain the same.

About Med BioGene Inc.

MBI is a life science company based in Vancouver, British Columbia that is currently focused on managing the license and rights to GeneFX® Lung, a prognostic genomic based test procedure. MBI's common shares are listed for trading on the Exchange. For more information, please visit www.medbiogene.com

For further information contact:

Iain Weir-Jones, Chief Executive Officer and Chairman of the Board of Directors
iainw@medbiogene.com
www.medbiogene.com